ATE83155T1 - Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke. - Google Patents

Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke.

Info

Publication number
ATE83155T1
ATE83155T1 AT88117833T AT88117833T ATE83155T1 AT E83155 T1 ATE83155 T1 AT E83155T1 AT 88117833 T AT88117833 T AT 88117833T AT 88117833 T AT88117833 T AT 88117833T AT E83155 T1 ATE83155 T1 AT E83155T1
Authority
AT
Austria
Prior art keywords
high ionic
plasma
protein formulations
recombination protein
ionic milieu
Prior art date
Application number
AT88117833T
Other languages
English (en)
Inventor
Ted C K Lee
Michael E Hrinda
Original Assignee
Rhone Poulenc Rorer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22354487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE83155(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhone Poulenc Rorer Int filed Critical Rhone Poulenc Rorer Int
Application granted granted Critical
Publication of ATE83155T1 publication Critical patent/ATE83155T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
AT88117833T 1987-10-29 1988-10-26 Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke. ATE83155T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11431487A 1987-10-29 1987-10-29
EP88117833A EP0314095B1 (de) 1987-10-29 1988-10-26 Plasma- und Rekombinationsproteinformulierungen in einem Milieu hoher Ionenstärke

Publications (1)

Publication Number Publication Date
ATE83155T1 true ATE83155T1 (de) 1992-12-15

Family

ID=22354487

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88117833T ATE83155T1 (de) 1987-10-29 1988-10-26 Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke.

Country Status (8)

Country Link
EP (1) EP0314095B1 (de)
JP (1) JP2544968B2 (de)
AT (1) ATE83155T1 (de)
AU (1) AU622133B2 (de)
CA (1) CA1329760C (de)
DE (1) DE3876600T2 (de)
ES (1) ES2053676T3 (de)
GR (1) GR3006506T3 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029765T2 (de) * 1989-07-24 1997-05-15 Bayer Ag Stabilisierung von hochgereinigten Proteinen
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
WO1993022336A1 (en) * 1992-04-30 1993-11-11 Alpha Therapeutic Corporation Improved solubilization and stabilization of factor viii complex
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US5514781A (en) * 1994-04-11 1996-05-07 Bayer Corporation Use of azoles as virucidal agents in solutions of biologically active proteins
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
GB9501040D0 (en) * 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
ZA983497B (en) 1997-04-28 1999-10-25 Lilly Co Eli Activated protein c formulations.
EP1561469A1 (de) * 1997-04-28 2005-08-10 Eli Lilly & Company Aktiviertes Protein C Formulierungen
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
ES2179414T3 (es) * 1997-11-22 2003-01-16 Roche Diagnostics Gmbh Procedimiento mejorado de estabilizacion de proteinas.
EP1820516B1 (de) 1999-02-22 2013-07-24 University of Connecticut Neue albuminfreie Faktor VIII Formulierungen
US7204981B2 (en) 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
US7087578B2 (en) 2000-05-24 2006-08-08 Eli Lilly And Company Formulations and methods for treating hypercoagulable states
JP2005530683A (ja) 2001-12-21 2005-10-13 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液体組成物
CN101912601B (zh) 2002-06-21 2012-08-29 诺和诺德医疗保健公司 因子vii多肽的稳定化固体组合物
WO2004007520A2 (en) * 2002-07-12 2004-01-22 Medarex, Inc. Methods and compositions for preventing oxidative degradation of proteins
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
AU2004288854B2 (en) * 2003-11-10 2009-10-01 Arriva-Pharmaceuticals, Inc. Dry recombinant human alpha 1-antitrypsin formulation
EP2311437A1 (de) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilisierte Zusammensetzungen von Faktor-VII-Polypeptiden
EP1854478A1 (de) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Formulierung eines Nikotine-Träger Impfstoffs
EP2150264A4 (de) * 2007-04-26 2014-09-24 Bayer Healthcare Llc Stabilisierung flüssiger lösungen eines rekombinanten proteins für gefrorene lagerung
EP2385825B1 (de) 2008-11-07 2018-10-10 University of Connecticut Faktor-viii-formulierungen
WO2012079979A1 (en) * 2010-12-16 2012-06-21 Novo Nordisk A/S Aqueous factor viii solution
BR112014009866A2 (pt) 2011-10-25 2018-09-04 Onclave Therapeutics Limited formulações de anticorpos e métodos
JP2015527350A (ja) * 2012-08-13 2015-09-17 ノヴォ ノルディスク アー／エス 第ｖｉｉｉ因子の液体製剤
CN108348458A (zh) * 2015-11-05 2018-07-31 诺和诺德股份有限公司 Fviii制剂
WO2019074886A1 (en) 2017-10-09 2019-04-18 Terumo Bct Biotechnologies, Llc LYOPHILIZATION CONTAINER AND METHOD OF USE
US11609042B2 (en) 2019-03-14 2023-03-21 Terumo Bct Biotechnologies, Llc Multi-part lyophilization container and method of use
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
EP4240757A2 (de) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Reinigung von fviii aus plasma mittels siliciumoxidadsorption

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3237512A1 (de) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
DE3609431A1 (de) * 1986-03-20 1987-09-24 Biotest Pharma Gmbh Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates

Also Published As

Publication number Publication date
EP0314095A1 (de) 1989-05-03
EP0314095B1 (de) 1992-12-09
ES2053676T3 (es) 1994-08-01
DE3876600T2 (de) 1993-04-15
AU622133B2 (en) 1992-04-02
JPH01149733A (ja) 1989-06-12
GR3006506T3 (de) 1993-06-30
DE3876600D1 (de) 1993-01-21
CA1329760C (en) 1994-05-24
AU2452088A (en) 1989-05-04
JP2544968B2 (ja) 1996-10-16

Similar Documents

Publication Publication Date Title
DE3876600D1 (de) Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke.
ATE76304T1 (de) Plasma- und rekombinationsproteinformulierungen in einem milieu niedriger ionenstaerke.
ATE198143T1 (de) Zahnpasten
FI873364A0 (fi) Foerfarande foer framstaellning av ett sytotoxiskt laekemedel.
DE69519580D1 (de) Zahnpflegemitteln
DK183386A (da) Sucralfatsuspension
NO933455L (no) Bis-naftalimider som inneholder aminosyreavledete linkere, for anvendelse som antikreftmidler
DK0700380T3 (da) N-Alkylthiopolyaminderivater som radioprotektive midler
MX9301450A (es) Recipiente con gases comprimidos para la utilizacion de polioxietilen-gliceril-oleatos
FI972384A7 (fi) Uudet dipeptidiset p-amidinobentsyyliamidit, jotka sisältävät N-termin aalisia sulfonyyli- tai amidinosulfonyyliryhmiä
ATE54325T1 (de) Haarwaschmittelzusammensetzung.
DE69432899D1 (de) Flüssige ionische Zusammensetzungen verwendende Ionenpunktquellen hoher Luminosität
ITRM920734A1 (it) Composizioni per la stabilizzazione dei polimeri. (caso 153-5550)
BR8901275A (pt) Composicao detergente aquosa,abrasiva,homogenea,despejavel
DE3560313D1 (en) Improvements in or relating to anticonvulsant agents
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
IT213815Z2 (it) Sega meccanica da traforo.
IT213814Z2 (it) Sega meccanica da traforo.
NO901452L (no) Blandinger inneholdende 2-tiocyano-metyltio-benzotiazol for anvendelse som industrielle mikrobiocider.
DK78788A (da) 4-substituerede benzamid-derivater og farmaceutiske midler indeholdende saadanne derivater
AU580890B2 (en) P-acylaminobenzamides
AU2817589A (en) Amino anthracenediones-bis platinum complexes, useful as antitumoral agents
BG40952A3 (en) Herbicide means
ES2034659T3 (es) Suspension acuosa estable de silico-aluminatos.
ATE68486T1 (de) 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl - 1h-imidazol.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time